CART Archives

Exploring Hidden Risks: New Study Investigates Causes of Nonrelapse Deaths in Cancer Patients Undergoing CAR-T Treatments

Recent findings indicate a concerning trend among cancer patients undergoing CAR-T cell therapies, with a significant portion of deaths attributed to causes unrelated to cancer relapse. The study, which delved deep into patient outcomes, sheds light on the need for enhanced patient monitoring and support systems during treatment. CAR-T therapy, a breakthrough in the treatment of blood cancers, involves modifying a patient’s T-cells to better recognize and destroy cancer cells. While the treatment has been …

FDA Panel Votes to Support CAR-T Therapies by Johnson & Johnson and Bristol Myers Squibb for Multiple Myeloma Treatment

Silver Spring, Maryland – An FDA advisory committee voted overwhelmingly in favor of recommending the approval of CAR-T therapies from Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee’s support for these therapies highlights a significant milestone in the ongoing discussions surrounding the use of CAR-T treatments in cancer care. During the committee meeting, concerns were raised about the higher rate of early deaths observed in …

New Concerns Arise Over Early Deaths in CAR-T Myeloma Trials with Carvykti and Abecma

Washington, D.C. – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T therapies used to treat multiple myeloma. Specifically, the FDA flagged the experimental treatments Carvykti from J&J and Legend, as well as Abecma from Bristol Myers Squibb. During the trials, patients receiving these CAR-T therapies experienced unexpected deaths, prompting the FDA to issue a warning. While CAR-T therapies have shown promising results in treating certain types …